The FDA on April 5, 2024, granted accelerated approval to ENHERTU® for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. ENHERTU® is a product of Daiichi Sankyo, Inc.
Bottom Ad
Advertisement
Subscribe
